Use of high-dose interferon in the treatment of chronic hepatitis C

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 25-34

  Shiffman, Mitchell L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

End of treatment response; High dose interferon; Induction dosing; Interferon; Interferon dose escalation; Sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032895233     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506
2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510
3. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-397
4. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502
5. Reichard O, Norkrans G, Fryden A, Braconier J, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group. Lancet 1998;351:83-87
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492
7. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432
8. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis [published erratum appears in N Engl J Med 1996;334:1143]. N Engl J Med 1995;332:1457-1462
9. Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996;24:21-26
10. Scullard GH, Pollard RB, Smith JL, et al. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 1981;143:772-783
11. Dusheiko G, Di Bisceglie A, Bowyer S, et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 1985;5:556-560
12. Hoofnagle JH, Smedile A, Mullen KD, et al. Treatment of chronic delta hepatitis with recombinant human alpha interferon [abstract]. Gastroenterology 1985;88:1665.
13. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-974
14. Genesca J, Esteban JI, Alter HJ. Blood-borne non-A, non-B hepatitis: hepatitis C. Semin Liver Dis 1991;11:147-164
15. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-278
16. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578
17. Thomson BJ, Doran M, Lever AM, Webster AD. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gamma-globulin replacement therapy. Lancet 1987;1:539-541
18. Arima T, Shimomura H, Nakagawa J. Treatment of non-A, non-B hepatitis with human fibroblast interferon [abstract]. Hepatology 1986;6:1117, Abstract 52
19. Lockner D, Bratt G, Lindborg A, Tornebohm E. Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon. Acta Med Scand 1987;221:413-415
20. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244: 359-362
21. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364
22. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993;38:612-618
23. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 1995;23:487-496
24. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-706
25. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-1249
26. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-165
27. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996;24:1034-1040
28. Toyoda H, Nakano S, Kumada T, et al. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C. Am J Gastroenterol 1996;91:743-747
29. Tassopoulos NC, Karvountzis G, Touloumi G, et al. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol 1996;91:1734-1738
30. Di Marco V, Lo Iacono O, Camma C, et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 1997;51:17-24
31. Imai Y, Kawata S, Tamura S, et al. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study. Liver 1997;17:88-92
32. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113:558-566
33. Farrell G, Cooksley WG, Dudley FJ, Watson K. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group. J Viral Hepat 1997;4:317-323
34. Fried MW, Shiffman ML, Sterling RK, et al. A multicenter, randomized trial of daily high dose interferon alfa-2b, for the treatment of chronic hepatitis C: prospective stratification by viral burden and genotype [abstract]. Gastroenterology 1998;114: A1242. Abstract L0180
35. Kagawa T, Hosoi K, Takashimizu S, et al. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C. Am J Gastroenterol 1998;93:192-196
36. Stewart CA, Hofmann CM, Luketic VA, Sanyal AJ, Sterling RK, Shiffman ML. A randomized controlled trial of daily vs three times weekly interferon alpha-2a in patients with chronic hepatitic HCV and either elevated or persistently normal ALT [abstract]. Gastroenterology 1997;114:A1345. Abstract L0605
37. Yamakawa Y, Sata M, Suzuki H, et al. Monitoring of serum levels of HCV RNA in early phase of IFN therapy; as a predictive marker of subsequent response. Hepatogastroenterology 1998; 45:133-136
38. Ouzan D, Babany G, Valla D, Opolon P. Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group. J Viral Hepat 1998;5:53-59
39. Degos F, Daurat V, Chevret S, et al. Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group. J Hepatol 1998;29:224-232
40. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26(suppl 1):71S-77S
41. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785
42. Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-704
43. Gretch DR. Use and interpretation of HCV diagnostic tests in the clinical setting. Clinics in Liver Disease 1997;1:543-558
44. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056
45. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C geno-type 1 virus with interferon alfa. Hepatology 1997;26:226-231
46. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatolology 1998;28:960-964
47. Bosch O, Tapia L, Quiroga JA, Carreno V. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C. J Hepatol 1993;17:146-149
48. Shiffman ML, Hofmann CM, Luketic VA, Thompson EB, Sanyal AJ. Treatment of chronic hepatitis C with escalating doses of interferon alpha-2b increases both biochemical and virologic response [abstract]. Hepatology 1995;22:152A. Abstract 184
49. Payen JL, Izopet J, Galindo-Migeot V, et al. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get.Vhc). Hepatology 1998; 28:1680-1686
50. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27: 1136-1143
51. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499
52. Fong TL, Morgan TR, Phan CG, Hoefs JC. Raising the dose of interferon does not improve the response in chronic hepatitis C. J Clin Gastroenterol 1995;20:42-44
53. Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Dig Dis Sci 1996;41:149-154
54. Ferenci P, Stauber R, Propst A, et al. Dose increase augments response rate to interferon-alpha in chronic hepatitis C. Dig Dis Sci 1996;41(12 suppl):103S-108S